REAL-WORLD SINGLE-CENTER CLINICAL DATA ON SORAFENIB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Publication Date : 01/07/2022
Publication link : 10.53011/JMRO.2022.01.03
Introduction. Hepatocellular carcinoma (HCC) is a malignant tumor that frequently develops in conjunction with chronic liver disease and cirrhosis. It is often identified late in its course, with a median survival of around 6 to 20 months following diagnosis. Although surgical excision is the gold standard of treatment, the majority of patients are ineligible due to tumor size or underlying liver disease. The hepatic reserve of the patient, as determined by the Child-Turcotte-Pugh classification, frequently influences treatment options. Method. Between January 2016 and June 2018, 42 patients admitted to Fundeni Clinical Institute's Department of Medical Oncology who had previously been treated with Sorafenib for more than two months were recruited in this retrospective analysis. We evaluated the etiology and stage of illness (BCLC), residual liver function (CHILD), performance status (ECOG), responsiveness to therapy and side events, progression-free survival, and overall survival. Results. With a median progression-free survival of 7.7 months and a median overall survival of 11.6 months, the study group had good outcomes in both the short and long terms. Among the most often reported adverse effects were skin rashes, diarrhea and hypertension. Conclusion. This retrospective, single-center study confirmed the benefit of sorafenib in the treatment of advanced HCC, particularly in patients with intact liver function and performance status.
No. of Downloads :